David Brown, MD
Show Description +
David Brown, MD, provides an overview of the 2-year outcomes of the TREX diabetic macular edema (DME) trial. Dr. Brown describes the three participating cohort groups in the trial of 150 eyes, with 30 eyes treated with monthly anti-VEGF injections for 2 years, 60 eyes treated with four ranibizumab injections (Lucentis, Genentech) and guided laser, and the remaining 60 eyes treated with four ranibizumab injections without guided laser. So far, the study has demonstrated that, with maintenance and a treat-and-extend regimen, visual acuity gains can be achieved both with and without guided laser.
Posted: 11/17/2017
David Brown, MD
David Brown, MD, provides an overview of the 2-year outcomes of the TREX diabetic macular edema (DME) trial. Dr. Brown describes the three participating cohort groups in the trial of 150 eyes, with 30 eyes treated with monthly anti-VEGF injections for 2 years, 60 eyes treated with four ranibizumab injections (Lucentis, Genentech) and guided laser, and the remaining 60 eyes treated with four ranibizumab injections without guided laser. So far, the study has demonstrated that, with maintenance and a treat-and-extend regimen, visual acuity gains can be achieved both with and without guided laser.
Posted: 11/17/2017
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2017.
Please log in to leave a comment.